AVAH · Aveanna Healthcare Holdings Inc. · Stock research

Current Thesis

The offset prior coverage kept naming — sponsor supply — arrived on a date. Aveanna announced a secondary on 2026-08-20 and priced it on 2026-08-21: 15,000,000 shares at $11.75, sold by affiliates of J.H. The company is offering no shares and receives none of the proceeds, so the share count is untouched and the transaction is purely a transfer of the sponsor's re-rating into cash at a marked price.

That price stamp lands eight days after the operating news. On 2026-08-13 Q2 revenue was $670.5M (+13.7% YoY) against $638.619M consensus, adjusted EPS $0.22 against $0.17, adjusted EBITDA $95.4M (+8.0% YoY, 14.2% of revenue), net income $40.3M versus $27.0M a year earlier, and FY2026 guidance moved to greater than $2.68B revenue and greater than $365M adjusted EBITDA from $338–$342M — the fourth raise of the documented 2026 sequence. Raymond James ($15, Strong Buy), BMO ($14, Outperform) and UBS ($13, Neutral) all repriced on 2026-08-14, the day after the print.

The adjusted daily series used for grading here carries a last completed close of $13.16, marked as of 2026-08-21, which is also the 52-week high; the shares are up 79.5% over three months and RSI(14) reads 81.4. The deal cleared at $11.75, below that reference close. Whether the post-deal tape has already closed that gap is not resolved by this series and is the first thing a reader should check before treating $13.16 as the working level. The narrative leg on offer from here is the fifth raise — that the >$365M EBITDA floor proves conservative in November

Bullish and bearish views on Aveanna Healthcare Holdings Inc.

The model's bull view on Aveanna Healthcare Holdings Inc. (AVAH), in brief: Fourth FY2026 raise, 2026-08-13. Adjusted EBITDA guidance to greater than $365M from $338–$342M; revenue to greater than $2.68B from $2.63–$2.65B. First-half adjusted EBITDA of $84.4M (Q1) and $95.4M (Q2) means the new floor requires a second-half step-up that management put in… The bear view: Third supply event of 2026, each at a higher price. Both cases follow in full.

Bull Case

• Fourth FY2026 raise, 2026-08-13. Adjusted EBITDA guidance to greater than $365M from $338–$342M; revenue to greater than $2.68B from $2.63–$2.65B. First-half adjusted EBITDA of $84.4M (Q1) and $95.4M (Q2) means the new floor requires a second-half step-up that management put in writing.
• Cash conversion held through the half. Year to date at 2026-07-04: operating cash flow $85.3M, free cash flow $75.4M, cash $97.2M, an undrawn $225.5M revolver and $110.0M of incremental securitization capacity — against a Q1 free-cash-flow deficit of $(3.8)M that was the cleanest bear objection in the spring.
• All three segments grew in Q2. Private Duty Services $553.9M (+14.0% YoY, 28.9% gross margin), Home Health & Hospice $69.0M (+14.8%, 53.9%), Medical Solutions $47.5M (+9.4%, 45.1%).
• The overhang now has a clearing price. Sponsor-affiliated sales printed at $6.24 (2026-06-03), $8.00 (2026-06-24) and $8.01 (2026-06-30). The 2026-08-21 deal moved 15,000,000 shares in one marketed transaction at $11.75 — an undated distribution risk converted into a dated one with a known level.
• Float widens with no dilution. Because the company issued nothing, per-share arithmetic is unchanged while tradable supply and daily liquidity rise, which is a precondition for the institutional buyer base the sell-side targets imply.
• Debt cost was cut before the print. The 2026-05-28 repricing lowered first-lien margins 0.50pp on a $1,318.4M term loan to SOFR + 3.75%, with a further 25bps contingent on a B2/B rating upgrade.
• Acquired revenue is already inside the run-rate. Family First Homecare closed 2026-06-01 for $175.5M cash (27 locations, seven states; expected ~$70M revenue and ~$10M EBITDA), funded from the balance sheet with cash still $97.2M at quarter-end.

Bear Case

• Third supply event of 2026, each at a higher price. June blocks at $6.24, $8.00 and $8.01; Every disclosed 2026 insider transaction has been a sale.

• Insiders sold alongside the fund. The selling group named in the 2026-08-21 release includes current and former directors and officers, not the sponsor alone.
• Margin spread narrowed. Q2 adjusted EBITDA grew 8.0% against revenue +13.7%; Q1 EBITDA growth was +25.2%. The full-year floor is a floor, and a result that lands at greater-than-$365M rather than well above it validates the guide without extending the re-rating.
• Floating-rate balance sheet into a swap expiry. $1,483.4M total debt against $97.2M cash at 2026-07-04, with the $520M notional swap expired in June 2026 — second-half interest expense is exposed to the SOFR path despite the May repricing.
• Reimbursement sets the top line. Private Duty Services, $553.9M of Q2 revenue, is largely state-Medicaid funded; state budget cycles reprice it independently of volume.
• Published targets bracket the tape rather than lead it. UBS at $13 (2026-08-14) sits below the $13.16 reference close and the highest published target is $15.

Setup & Price Structure

The narrative is maturing. The fundamental cadence is intact and dated — four raises, most recently 2026-08-13 — and price is at or near its 52-week high. What dates the label rather than accelerating is the shape of the flow around it: the three target raises came on 2026-08-14, one day after the print; the visible coverage in the last week is premarket movers lists (Benzinga, 2026-08-20 and 2026-08-21) rather than new dedicated work; It is not saturated — the guide is still being raised and the seller is a scheduled sponsor unwind rather than a broken fundamental — but the marginal buyer this month was an underwriting book, not a new constituency.

Observable positioning and crowding facts as of 2026-08-21: distance from the 52-week high 0.0%; RSI(14) 81.4; three-month price change +79.5%; no scheduled company event for roughly eleven weeks; and a marketed clearing price of $11.75 established below the last completed close of $13.16.

$10.32 was the pre-print 52-week high and the ceiling above which all published targets sat before 2026-08-13; it is the shelf the guidance raise created. The published target band runs $13 (UBS) to $15 (Raymond James), with Barclays at $9.50 (2026-07-09) and Truist at $11 (2026-07-14) not yet refreshed in the material reviewed.

Catalyst Calendar (next 30 days)

• ~2026-08-25 to ~2026-08-27 (est.) — Form 4 filings from the selling directors and officers, due within two business days of execution; the June 2026 sponsor filings appeared on that cadence.
• ~2026-09-20 (est.) — Expiry of the 30-day option over 2,250,000 additional shares granted to RBC Capital Markets on 2026-08-21. Exercise or lapse is observable.
• ~2026-11-01 (est., unconfirmed) — CMS CY2027 Home Health PPS final rule. The CY2026 rule finalized a 1.3% aggregate home-health payment decrease; Home Health & Hospice was $69.0M of Q2 revenue at a 53.9% gross margin.
• ~2026-11-05 (est.) — Q3 FY2026 print. Outside the 30-day window, and named because nothing else scheduled sits between now and then.

Elapsed catalysts

• 2026-08-24 (passed 2d ago)

What Would Change Our Mind

The structure at risk is the shelf built on 2026-08-13, now with a marked seller sitting on top of it. The condition that breaks the leg is a weekly close below $11.75 — under the price at which 15,000,000 sponsor and insider shares cleared on 2026-08-21 — A subsequent weekly close below $10.32 would forfeit the pre-print ceiling entirely and put price back inside the range the guidance raise broke it out of.

Three non-price developments would do the same work. A FY2026 guide maintained rather than raised at the ~November print ends the cadence that produced the re-rating in the first place. A Q3 adjusted EBITDA margin below the 14.2% of revenue posted in Q2, or first-half free cash flow of $75.4M failing to extend in the second half, would break the cash-conversion argument that answered the spring bear case.

What would strengthen it: the over-allotment lapsing unexercised at ~2026-09-20 with weekly closes holding above $11.75, which would mark the deal as absorbed rather than as the top of the distribution.

Correlation Notes

• Home-health and Medicaid-services peers — BrightSpring (BTSG), Addus HomeCare (ADUS), Enhabit (EHAB), Pennant Group (PNTG). CMS rule dates and state budget headlines move the group as a block, so the ~2026-11-01 final rule is a sector event, not a single-name one.
• Rate sensitivity is unusual for a services small cap. With $1,483.4M of mostly floating-rate debt at 2026-07-04 and the $520M swap expired, SOFR moves feed earnings directly; the name will track rate expectations more closely than an unlevered peer.
• Small-cap beta cuts both ways after +79.5% in three months. Index-level small-cap drawdowns are amplified in names that have run this far above longer moving averages.
• Sponsor-exit cohort. For post-IPO, PE-backed small caps the near-term driver is the supply calendar — option exercises, block trades, remaining registered shares — which correlates across the cohort independently of operating results.